Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma

Balazs Hegedus, Debasish Banerjee, Tu Hsueh Yeh, Stefan Rothermich, Arie Perry, Joshua B. Rubin, Joel R. Garbow, David H. Gutmann

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Mouse models of human cancers afford unique opportunities to evaluate novel therapies in preclinical trials. For this purpose, we analyzed three genetically engineered mouse (GEM) models of low-grade glioma resulting from either inactivation of the neurofibromatosis-1 (Nf1) tumor suppressor gene or constitutive activation of KRas in glial cells. Based on tumor proliferation, location, and penetrance, we selected one of these Nf1 GEM models for preclinical drug evaluation. After detection of an optic glioma by manganese-enhanced magnetic resonance imaging, we randomized mice to either treatment or control groups. We first validated the Nf1 optic glioma model using conventional single-agent chemotherapy (temozolomide) currently used for children with low-grade glioma and showed that treatment resulted in decreased proliferation and increased apoptosis of tumor cells in vivo as well as reduced tumor volume. Because neurofibromin negatively regulates mammalian target of rapamycin (mTOR) signaling, we showed that pharmacologic mTOR inhibition in vivo led to decreased tumor cell proliferation in a dose-dependent fashion associated with a decrease in tumor volume. Interestingly, no additive effect of combined rapamycin and temozolomide treatment was observed. Lastly, to determine the effect of these therapies on the normal brain, we showed that treatments that affect tumor cell proliferation or apoptosis did not have a significant effect on the proliferation of progenitor cells within brain germinal zones. Collectively, these findings suggest that this Nf1 optic glioma model may be a potential preclinical benchmark for identifying novel therapies that have a high likelihood of success in human clinical trials.

Original languageEnglish
Pages (from-to)1520-1528
Number of pages9
JournalCancer Research
Volume68
Issue number5
DOIs
Publication statusPublished - Mar 1 2008
Externally publishedYes

Fingerprint

Optic Nerve Glioma
Neurofibromatosis 1
temozolomide
Sirolimus
Neoplasms
Tumor Burden
Glioma
Therapeutics
Neurofibromin 1
Cell Proliferation
Apoptosis
Benchmarking
Preclinical Drug Evaluations
Penetrance
Brain
Manganese
Tumor Suppressor Genes
Neuroglia
Stem Cells
Magnetic Resonance Imaging

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hegedus, B., Banerjee, D., Yeh, T. H., Rothermich, S., Perry, A., Rubin, J. B., ... Gutmann, D. H. (2008). Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Research, 68(5), 1520-1528. https://doi.org/10.1158/0008-5472.CAN-07-5916

Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. / Hegedus, Balazs; Banerjee, Debasish; Yeh, Tu Hsueh; Rothermich, Stefan; Perry, Arie; Rubin, Joshua B.; Garbow, Joel R.; Gutmann, David H.

In: Cancer Research, Vol. 68, No. 5, 01.03.2008, p. 1520-1528.

Research output: Contribution to journalArticle

Hegedus, B, Banerjee, D, Yeh, TH, Rothermich, S, Perry, A, Rubin, JB, Garbow, JR & Gutmann, DH 2008, 'Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma', Cancer Research, vol. 68, no. 5, pp. 1520-1528. https://doi.org/10.1158/0008-5472.CAN-07-5916
Hegedus, Balazs ; Banerjee, Debasish ; Yeh, Tu Hsueh ; Rothermich, Stefan ; Perry, Arie ; Rubin, Joshua B. ; Garbow, Joel R. ; Gutmann, David H. / Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. In: Cancer Research. 2008 ; Vol. 68, No. 5. pp. 1520-1528.
@article{b7d41a55b95f4d489190d7b572015149,
title = "Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma",
abstract = "Mouse models of human cancers afford unique opportunities to evaluate novel therapies in preclinical trials. For this purpose, we analyzed three genetically engineered mouse (GEM) models of low-grade glioma resulting from either inactivation of the neurofibromatosis-1 (Nf1) tumor suppressor gene or constitutive activation of KRas in glial cells. Based on tumor proliferation, location, and penetrance, we selected one of these Nf1 GEM models for preclinical drug evaluation. After detection of an optic glioma by manganese-enhanced magnetic resonance imaging, we randomized mice to either treatment or control groups. We first validated the Nf1 optic glioma model using conventional single-agent chemotherapy (temozolomide) currently used for children with low-grade glioma and showed that treatment resulted in decreased proliferation and increased apoptosis of tumor cells in vivo as well as reduced tumor volume. Because neurofibromin negatively regulates mammalian target of rapamycin (mTOR) signaling, we showed that pharmacologic mTOR inhibition in vivo led to decreased tumor cell proliferation in a dose-dependent fashion associated with a decrease in tumor volume. Interestingly, no additive effect of combined rapamycin and temozolomide treatment was observed. Lastly, to determine the effect of these therapies on the normal brain, we showed that treatments that affect tumor cell proliferation or apoptosis did not have a significant effect on the proliferation of progenitor cells within brain germinal zones. Collectively, these findings suggest that this Nf1 optic glioma model may be a potential preclinical benchmark for identifying novel therapies that have a high likelihood of success in human clinical trials.",
author = "Balazs Hegedus and Debasish Banerjee and Yeh, {Tu Hsueh} and Stefan Rothermich and Arie Perry and Rubin, {Joshua B.} and Garbow, {Joel R.} and Gutmann, {David H.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-07-5916",
language = "English",
volume = "68",
pages = "1520--1528",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma

AU - Hegedus, Balazs

AU - Banerjee, Debasish

AU - Yeh, Tu Hsueh

AU - Rothermich, Stefan

AU - Perry, Arie

AU - Rubin, Joshua B.

AU - Garbow, Joel R.

AU - Gutmann, David H.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Mouse models of human cancers afford unique opportunities to evaluate novel therapies in preclinical trials. For this purpose, we analyzed three genetically engineered mouse (GEM) models of low-grade glioma resulting from either inactivation of the neurofibromatosis-1 (Nf1) tumor suppressor gene or constitutive activation of KRas in glial cells. Based on tumor proliferation, location, and penetrance, we selected one of these Nf1 GEM models for preclinical drug evaluation. After detection of an optic glioma by manganese-enhanced magnetic resonance imaging, we randomized mice to either treatment or control groups. We first validated the Nf1 optic glioma model using conventional single-agent chemotherapy (temozolomide) currently used for children with low-grade glioma and showed that treatment resulted in decreased proliferation and increased apoptosis of tumor cells in vivo as well as reduced tumor volume. Because neurofibromin negatively regulates mammalian target of rapamycin (mTOR) signaling, we showed that pharmacologic mTOR inhibition in vivo led to decreased tumor cell proliferation in a dose-dependent fashion associated with a decrease in tumor volume. Interestingly, no additive effect of combined rapamycin and temozolomide treatment was observed. Lastly, to determine the effect of these therapies on the normal brain, we showed that treatments that affect tumor cell proliferation or apoptosis did not have a significant effect on the proliferation of progenitor cells within brain germinal zones. Collectively, these findings suggest that this Nf1 optic glioma model may be a potential preclinical benchmark for identifying novel therapies that have a high likelihood of success in human clinical trials.

AB - Mouse models of human cancers afford unique opportunities to evaluate novel therapies in preclinical trials. For this purpose, we analyzed three genetically engineered mouse (GEM) models of low-grade glioma resulting from either inactivation of the neurofibromatosis-1 (Nf1) tumor suppressor gene or constitutive activation of KRas in glial cells. Based on tumor proliferation, location, and penetrance, we selected one of these Nf1 GEM models for preclinical drug evaluation. After detection of an optic glioma by manganese-enhanced magnetic resonance imaging, we randomized mice to either treatment or control groups. We first validated the Nf1 optic glioma model using conventional single-agent chemotherapy (temozolomide) currently used for children with low-grade glioma and showed that treatment resulted in decreased proliferation and increased apoptosis of tumor cells in vivo as well as reduced tumor volume. Because neurofibromin negatively regulates mammalian target of rapamycin (mTOR) signaling, we showed that pharmacologic mTOR inhibition in vivo led to decreased tumor cell proliferation in a dose-dependent fashion associated with a decrease in tumor volume. Interestingly, no additive effect of combined rapamycin and temozolomide treatment was observed. Lastly, to determine the effect of these therapies on the normal brain, we showed that treatments that affect tumor cell proliferation or apoptosis did not have a significant effect on the proliferation of progenitor cells within brain germinal zones. Collectively, these findings suggest that this Nf1 optic glioma model may be a potential preclinical benchmark for identifying novel therapies that have a high likelihood of success in human clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=40449092253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449092253&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-5916

DO - 10.1158/0008-5472.CAN-07-5916

M3 - Article

C2 - 18316617

AN - SCOPUS:40449092253

VL - 68

SP - 1520

EP - 1528

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 5

ER -